Navigation Links
Art Pappas Elected to NVCA Board of Directors
Date:5/15/2013

RESEARCH TRIANGLE PARK, N.C., May 15, 2013 /PRNewswire/ -- The National Venture Capital Association (NVCA) today announced the election of Arthur M. Pappas , managing partner of Pappas Ventures, to its board of directors. He will serve a four-year term. The appointment was made official at the association's annual meeting – VentureScape 2013 – in San Francisco.

Mr. Pappas has over 30 years of operating experience as a pharmaceutical and biotechnology industry executive and venture capital investor in life science companies. He founded Pappas Ventures in 1994, and works with a team that has invested in numerous life science companies that have created novel innovative products addressing unmet medical needs. Prior to forming Pappas Ventures, he held senior level leadership positions at several multinational pharmaceutical companies, for which he led operations and was responsible for the development, licensing and launch of a number of global products.

The NVCA serves as the venture capital community's trade association, representing more than 400 members by advocating for policies that encourage innovation and reward long term investment.

"It is an honor and a pleasure to join the NVCA Board of Directors, especially during such a critical time for the venture capital industry," said Mr. Pappas. "I look forward to working with the organization and the board in developing policies that can further foster innovation and facilitate the creation of good jobs throughout the U.S. economy."

The NVCA also appointed Josh Green , general partner of Mohr Davidow Ventures to serve as the 2013-2014 Chairman of the Board of Directors, effective immediately. Mr. Pappas joins the board along with five other newly-elected directors; Scott Kupor , Andreessen Horowitz; Sue Siegel , GE healthymagination; John Backus , New Atlantic Ventures; Mark Leschly , Rho Capital Partners; and Jim Healy , Sofinnova Ventures.

About Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of more than 50 life sciences companies, including Arena Pharmaceuticals (Nasdaq: ARNA), Plexxikon (acquired by Daiichi Sankyo), Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), NuVasive (Nasdaq: NUVA), TESARO (Nasdaq: TSRO), and Chimerix (Nasdaq: CMRX). For more information about Pappas Ventures please visit www.pappasventures.com.

CONTACT:
Ford S. Worthy
fworthy@pappasventures.com
919-998-3330

 


'/>"/>
SOURCE Pappas Ventures
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SoundConnect Recently Selected by iCIMS, Inc.
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. ExakTime’s GeoTrakker Selected for 2013 Most Innovative Product Award Program
4. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
5. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
6. American Physical Society elected physicist Markus Aspelmeyer as a Fellow
7. Topricin Selected for Bruce Springsteen MusiCares’ Tribute Gala
8. Topricin Pain Relief and Healing Cream Selected by Healthy Holistic Living as one of the Top 100 Green Products of 2012
9. INRS: Professor Federico Rosei elected AAAS Fellow in recognition of his meritorious efforts to advance science
10. Cantrell Selected to Lead Kansas Bioscience Authority
11. Companies Selected to Present at AdvaMed 2012 Announced
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:6/9/2016)... June 9, 2016 Paris ... Teleste,s video security solution to ensure the safety of people ... during the major tournament Teleste, an international ... and services, announced today that its video security solution will ... to back up public safety across the country. The system ...
(Date:6/2/2016)... , June 2, 2016   The Weather Company ... announcing Watson Ads, an industry-first capability in which consumers will ... being able to ask questions via voice or text and ... Marketers have long sought an ... consumer, that can be personal, relevant and valuable; and can ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):